Triglav Skladi D.O.O. Buys 900 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Triglav Skladi D.O.O. increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,920 shares of the medical equipment provider’s stock after acquiring an additional 900 shares during the quarter. Triglav Skladi D.O.O.’s holdings in Intuitive Surgical were worth $3,923,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of ISRG. Brighton Jones LLC grew its position in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock worth $1,916,000 after acquiring an additional 731 shares during the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider’s stock worth $99,678,000 after buying an additional 883 shares during the last quarter. Advisors Capital Management LLC grew its position in shares of Intuitive Surgical by 6.0% in the 4th quarter. Advisors Capital Management LLC now owns 2,912 shares of the medical equipment provider’s stock worth $1,520,000 after buying an additional 165 shares during the last quarter. Mariner LLC grew its position in shares of Intuitive Surgical by 5.1% in the 4th quarter. Mariner LLC now owns 89,122 shares of the medical equipment provider’s stock worth $46,520,000 after buying an additional 4,327 shares during the last quarter. Finally, CreativeOne Wealth LLC grew its position in shares of Intuitive Surgical by 87.8% in the 4th quarter. CreativeOne Wealth LLC now owns 4,986 shares of the medical equipment provider’s stock worth $2,602,000 after buying an additional 2,331 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Intuitive Surgical

In related news, insider Gary S. Guthart sold 2,800 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $495.24, for a total value of $1,386,672.00. Following the sale, the insider directly owned 18,520 shares in the company, valued at approximately $9,171,844.80. The trade was a 13.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the business’s stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president owned 907 shares in the company, valued at $510,740.77. This represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 15,859 shares of company stock valued at $7,908,248. Company insiders own 0.70% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG opened at $478.19 on Wednesday. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00. The firm has a market capitalization of $171.42 billion, a P/E ratio of 66.69, a PEG ratio of 4.95 and a beta of 1.59. The business has a fifty day moving average of $513.42 and a 200 day moving average of $527.10.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The company had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. During the same quarter in the previous year, the company posted $1.78 earnings per share. Intuitive Surgical’s revenue was up 21.4% compared to the same quarter last year. Analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. UBS Group lifted their price objective on Intuitive Surgical from $547.00 to $585.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut Intuitive Surgical from a “hold” rating to a “sell” rating and lowered their target price for the company from $515.00 to $440.00 in a research note on Monday, June 9th. Piper Sandler restated an “overweight” rating and issued a $595.00 target price (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Evercore ISI raised their target price on Intuitive Surgical from $470.00 to $550.00 and gave the company an “in-line” rating in a research note on Tuesday, July 8th. Finally, Wells Fargo & Company lifted their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the company an “overweight” rating in a research note on Wednesday, July 23rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus target price of $595.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.